The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis

Clinical and Experimental Immunology

Volumn 183, Issue 3, 2016, Pages 397-404

  Ruscitti, Piero ^a   Ciccia, F ^b   Cipriani, P ^a   Guggino, G ^b   Di Benedetto, P ^a   Rizzo, A ^c   Liakouli, V ^a   Berardicurti, O ^a   Carubbi, F ^a   Triolo, G ^b   Giacomelli, R ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Ospedali Riuniti Villa Sofia Cervello   (Italy)

Author keywords

Adult onset Still's disease; H ferritin; Hyperferritinaemic syndrome; Macrophage

Indexed keywords

CD68 ANTIGEN; FERRITIN; H FERRITIN; L FERRITIN; UNCLASSIFIED DRUG; APOFERRITIN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; LYMPH NODE BIOPSY; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE LEVEL; AGED; BIOPSY; BLOOD; CHEMISTRY; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; ULTRASTRUCTURE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOFERRITINS; BIOPSY; FEMALE; FERRITINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPH NODES; MACROPHAGES; MALE; MIDDLE AGED; STILL'S DISEASE, ADULT-ONSET;

EID: 84958831914     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12738     Document Type: Article

References (51)

1. Maria AT, Le Quellec A, Jorgensen C et al. Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 2014; 13:1149-59.
2. Cipriani P, Ruscitti P, Carubbi F et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol 2014; 33:49-55.
3. Kim YJ, Koo BS, Kim YG et al. Clinical features and prognosis in 82 patients with adult-onset Still's disease. Clin Exp Rheumatol 2014; 32:28-33.
4. Kim HA, Kwon JE, Yim H et al. The pathologic findings of skin, lymph node, liver, and bone marrow in patients with adult-onset still disease: a comprehensive analysis of 40 cases. Medicine (Balt) 2015; 94:e787
5. Rosário C, Zandman-Goddard G, Meyron-Holtz EG et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013; 11:185
6. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009; 10:387-92.
7. Zandman-Goddard G, Shoenfeld Y. Hemophagocytic syndrome with hyperferritinemia: a stormy immunological response. Isr Med Assoc J 2013; 15:187-8.
8. Wang W, Knovich MA, Coffman LG et al. Serum ferritin: past, present and future. Biochim Biophys Acta 2010; 1800:760-9.
9. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99:3505-16.
10. Cohen LA, Gutierrez L, Weiss A et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 2010; 116:1574-84.
11. Recalcati S, Invernizzi P, Arosio P et al. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 2008; 30:84-9.
12. Hann HW, Stahlhut MW, Lee S et al. Effects of isoferritins on human granulocytes. Cancer 1989; 63:2492-6.
13. Morikawa K, Oseko F, Morikawa S. H and L-rich ferritins suppress antibody production, but not proliferation, of human B lymphocytes in vitro. Blood 1994; 83:737-43.
14. Broxmeyer HE, Bognacki J, Dorner MH et al. Identification of leukemia-associated inhibitory activity as acidic isoferritins. A regulatory role for acidic isoferritins in the production of granulocytes and macrophages. J Exp Med 1981; 153:1426-44.
15. Gray CP, Franco AV, Arosio P et al. Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production. Int J Cancer 2001; 92:843-50.
16. Li R, Luo C, Mines M et al. Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain. J Biol Chem 2006; 281:37616-27.
17. Ruddell RG, Hoang-Le D, Barwood JM et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 2009; 49:887-900.
18. Chen TT, Li L, Chung DH et al. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med 2005; 202:955-65.
19. Kuchroo VK, Umetsu DT, DeKruyff RH et al. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol 2003; 3:454-62.
20. Chakravarti S, Sabatos CA, Xiao S et al. Tim-2 regulates T helper type 2 responses and autoimmunity. J Exp Med 2005; 202:437-44.
21. Knickelbein JE, de Souza AJ, Tosti R et al. Cutting edge: inhibition of T cell activation by TIM-2. J Immunol 2006; 177:4966-70.
22. Smith EP, Shanks K, Lipsky MM et al. Expression of neuroimmune semaphorins 4A and 4D and their receptors in the lung is enhanced by allergen and vascular endothelial growth factor. BMC Immunol 2011; 12:30.
23. Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK et al. The costimulatory role of TIM molecules. Immunol Rev 2009; 229:259-70.
24. Gordon S, Plüddemann A, Mukhopadhyay S. Sinusoidal immunity: macrophages at the lymphohematopoietic interface. Cold Spring Harb Perspect Biol 2014; 7:a016378.
25. Yamaguchi M, Ohta A, Tsunematsu T et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19:424-30.
26. Cush JJ, Medsger TA Jr, Christy WC et al. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987; 30:186-94.
27. Pouchot J, Sampalis JS, Beaudet F et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Balt) 1991; 70:118-36.
28. Jeon YK, Paik JH, Park SS et al. Spectrum of lymph node pathology in adult onset Still's disease; analysis of 12 patients with one follow up biopsy. J Clin Pathol 2004; 57:1052-6.
29. Ramos-Casals M, Brito-Zerón P, López-Guillermo A et al. Adult haemophagocytic syndrome. Lancet 2014; 383:1503-16.
30. Knovich MA, Storey JA, Coffman LG et al. Ferritin for the clinician. Blood Rev 2009; 23:95-104.
31. Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol 2015; 33:643-75.
32. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013; 496:445-55.
33. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity 2014; 41:21-35.
34. Smirnov IM, Bailey K, Flowers CH et al. Effects of TNF-alpha and IL-1beta on iron metabolism by A549 cells and influence on cytotoxicity. Am J Physiol 1999; 277:L257-63.
35. Wei Y, Miller SC, Tsuji Y et al. Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun 1990; 169:289-96.
36. Piñero DJ, Hu J, Cook BM et al. Interleukin-1beta increases binding of the iron regulatory protein and the synthesis of ferritin by increasing the labile iron pool. Biochim Biophys Acta 2000; 1497:279-88.
37. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011; 12:715-23.
38. Chen DY, Lan JL, Lin FJ et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004; 31:2189-98.
39. Silva-Gomes S, Bouton C, Silva T et al. Mycobacterium avium infection induces H-ferritin expression in mouse primary macrophages by activating Toll-like receptor 2. PLOS ONE 2013; 8:e82874.
40. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007; 6:457-63.
41. Colafrancesco S, Priori R, Alessandri C et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res 2014; 60:177-83.
42. Régent A, Ly KH, Blet A et al. Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. Ann Rheum Dis 2013; 72:1269-70.
43. Baerlecken NT, Linnemann A, Gross WL et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 2012; 71:943-7.
44. Matsui K, Tsuchida T, Hiroishi K et al. High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still's disease. Rheumatology (Oxf) 1999; 38:477-8.
45. Jung S-Y, Park Y-B, Ha Y-J et al. Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease. J Rheumatol 2010; 37:1029-34.
46. Zou Y-Q, Lu L-J, Li S-J et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease. Clin Biochem 2008; 41:519-24.
47. Benahmed F, Ely S, Lu TT. Lymph node vascular-stromal growth and function as a potential target for controlling immunity. Clin Immunol 2012; 144:109-16.
48. Malhotra D, Fletcher AL, Turley SJ. Stromal and hematopoietic cells in secondary lymphoid organs: partners in immunity. Immunol Rev 2013; 251:160-76.
49. Gerfaud-Valentin M, Maucort-Boulch D, Hot A et al. Adult onset Still's disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine (Balt) 2014; 93:91-9.
50. Ruscitti P, Cipriani P, Di Benedetto P et al. Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmun Rev 2015; 14:429-37.
51. Gerfaud-Valentin M, Jamilloux Y, Iwaz J et al. Adult-onset Still's disease. Autoimmun Rev 2014; 13:708-22.